<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Genovese, Mark C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Naïve to Biologic Therapy or Inadequate Responders to TNF-α Inhibitors: A Phase 2 Study of LY2439821</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Evidence from both animal and human models regarding the proinflammatory cytokine interleukin-17 (IL-17) and the T-helper cell (Th17) that secretes it provides a compelling rationale for therapeutic targeting of IL-17 in rheumatoid arthritis (RA). Ixekizumab (LY2439821) is a humanized monoclonal antibody that is used in the treatment of autoimmune diseases [Peck A and Mellins ED. Infect Immun 2010; Sarkar S and Fox DA. Rheum Dis Clin North Am 2010]. This article presents results from an international Phase 2, 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy [NCT00966875].</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>